Mylan gets OK for generic of Pfizer allergy drug

NEW YORK (Reuters) - Drug maker Mylan Inc MYL.N said on Friday that it will immediately start shipping a generic version of Pfizer Inc's PFE.N allergy drug Zyrtec after receiving final U.S. regulatory approval.

The U.S. Food and Drug Administration granted Mylan approval of its abbreviated new drug applications for 5 and 10 milligram tablets of Cetirizine Hydrochloride tablets, the company said in a statement.

The tablets are a generic version of Pfizer’s Zyrtec, which had U.S. sales of about $1.4 billion for the 12 months ended September 30, Mylan said.

Zyrtec, an antihistamine, treats indoor and outdoor allergy symptoms in adults and children as well as itching due to chronic hives.

Reporting by Chris Reiter and Purwa Khandelwal in Bangalore; Editing by Gopakumar Warrier and Dave Zimmerman